Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
Nuvectis Pharma, a clinical-stage biopharmaceutical company focused on treatments for immune complement-related conditions and oncology, announced the pricing of its $100 million public offering of 5 million common shares at $20.00 per share. The offering aims to raise capital to fund development programs for drug candidates NXP100, NXP200, and NXP…